
ESMO BREAST CANCER 2025 SATELLITE SYMPOSIUM



SPEAKERS



Peter Fasching (chair)
University Hospital Erlangen
Comprehensive Cancer Center



Hope Rugo
University of California San
Francisco Helen Diller Family
Comprehensive Cancer Center



Fatima Cardoso
ABC Global Alliance

AGENDA

- Welcome and introduction
- Evolution of risk in patients with HR+ EBC
- Patient 1: Node-positive EBC
- Patient 2: Node-negative EBC and high-risk characteristics
- Patient 3: Clinically aggressive ABC
- Key takeaways and live Q&A

This symposium is organized and funded by Novartis Pharma AG in the context of the ESMO BC Congress 2025 in Munich, Germany.

This medical education event is solely intended for non-US physicians and pharmacists only. This scientific information may include data/information on investigational uses of compounds/drugs that have not been approved by regulatory authorities.

Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the Summary of Product Characteristics (SmPC) or product information approved in your local country

